Fernández-Pérez L, Flores-Morales A, Chirino-Godoy R, Díaz-Chico J C, Díaz-Chico B N
Molecular Endocrinology Group, Department of Clinical Sciences, Faculty of Health Sciences, University of Las Palmas of Gran Canaria-Canary Institute for Cancer Research, Spain.
J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):336-43. doi: 10.1016/j.jsbmb.2008.03.019. Epub 2008 Mar 14.
Steroid hormones activate target cells through specific receptors that discriminate among ligands based upon recognition of distinct structural features. For most known steroids, membrane and nuclear receptors co-exist in many target cells. However, while the structure of the nuclear receptors and their function as transcriptional activators of specific target genes is generally well understood, the identity of the membrane receptors remains elusive. Using pharmacological and biochemical approaches, we are beginning to characterize receptors for glucocorticoids and anabolic-androgenic steroids in male rat liver membranes. Male rat liver endoplasmic reticulum contains two steroid binding sites which are functionally related and associated with a 90-134 kDa oligomeric protein: (1) the low-affinity glucocorticoid binding site (LAGS), composed at least in part of two peptides (37 and 53 kDa) that bind glucocorticoids and (2) the stanozolol binding protein (STBP), composed at least in part of three peptides (22, 31, and 55 kDa) that bind the synthetic androgen stanozolol. These steroid binding proteins have many properties different from those of classical nuclear receptors, with the salient differences being a failure to recognize "classical" ligands for nuclear receptors together with marked differences in biochemical properties and physiological regulation. The mechanism of interaction of glucocorticoids with the LAGS can be clearly distinguished from that with STBP. Moreover, STBP shows an extremely narrow pharmacological profile, being selective for ST and its analog, danazol, among more than 100 steroids and non-steroidal compounds that were assayed, including those that are able to displace glucocorticoids from the LAGS. The level of LAGS activity undergoes dramatic variations following changes from the physiological serum levels of thyroid hormones, glucocorticoids, GH, vitamin A, and E2. However, neither thyroid hormones nor GH have a critical role on STBP activity. The STBP is functionally related to LAGS. We have suggested a novel mechanism for STBP whereby membrane-associated glucocorticoid binding activity is targeted by stanozolol (and 16beta-hydroxylated stanozolol): stanozolol modulates glucocorticoid activity in the liver through negative allosteric modulation of the LAGS resulting in an effective increase in classical GR-signaling by increasing glucocorticoid availability to the cytosolic GR.
类固醇激素通过特定受体激活靶细胞,这些受体基于对不同结构特征的识别来区分配体。对于大多数已知的类固醇而言,膜受体和核受体在许多靶细胞中共存。然而,虽然核受体的结构及其作为特定靶基因转录激活剂的功能已基本为人所知,但膜受体的身份仍然难以捉摸。我们正采用药理学和生物化学方法,开始对雄性大鼠肝细胞膜中糖皮质激素和合成代谢雄激素类固醇的受体进行表征。雄性大鼠肝脏内质网含有两个在功能上相关且与一种90 - 134 kDa寡聚蛋白相关的类固醇结合位点:(1)低亲和力糖皮质激素结合位点(LAGS),至少部分由两种结合糖皮质激素的肽(37 kDa和53 kDa)组成;(2)司坦唑醇结合蛋白(STBP),至少部分由三种结合合成雄激素司坦唑醇的肽(22 kDa、31 kDa和55 kDa)组成。这些类固醇结合蛋白具有许多与经典核受体不同的特性,显著差异在于无法识别核受体的“经典”配体,以及在生化特性和生理调节方面存在明显差异。糖皮质激素与LAGS的相互作用机制可与它与STBP的相互作用机制明显区分开来。此外,STBP显示出极其狭窄的药理学谱,在超过100种被检测的类固醇和非类固醇化合物中,包括那些能够从LAGS上取代糖皮质激素的化合物,它对司坦唑醇及其类似物达那唑具有选择性。甲状腺激素、糖皮质激素、生长激素、维生素A和雌二醇的血清生理水平发生变化后,LAGS活性水平会发生显著变化。然而,甲状腺激素和生长激素对STBP活性均无关键作用。STBP在功能上与LAGS相关。我们提出了一种关于STBP的新机制,即膜相关的糖皮质激素结合活性被司坦唑醇(和16β - 羟基化司坦唑醇)靶向:司坦唑醇通过对LAGS的负别构调节来调节肝脏中的糖皮质激素活性,从而通过增加糖皮质激素对胞质糖皮质激素受体(GR)的可用性有效地增强经典GR信号传导。